1. Early steps in fusion between Epstein-Barr virus and a human hepatoma cell line (Li7A).
- Author
-
Lisi A, Pozzi D, Iacovacci S, Carloni G, Lanzilli G, De Ros I, Ravagnan G, and Grimaldi S
- Subjects
- Cell Membrane metabolism, Complement C3d pharmacology, Hematopoietic Stem Cells microbiology, Humans, Kinetics, Lymphocytes microbiology, Receptors, Complement analysis, Receptors, Complement 3d, Tumor Cells, Cultured, Carcinoma, Hepatocellular microbiology, Herpesvirus 4, Human growth & development, Liver Neoplasms microbiology, Membrane Fusion drug effects, Receptors, Virus metabolism
- Abstract
Epstein-Barr virus, the causative agent of mononucleosis and several human cancers, infects cells via complement receptor type 2 (CR2). Expression of this receptor is restricted to B lymphocytes, some epithelial cells and immature thymocytes; expression of CR2-like proteins has been also found on T cells. In the present report, we identified the presence, on the membrane of Li7A cells, of a novel EBV receptor distinct from CR2 capable of triggering fusion with EBV virions with more rapid kinetics than that found with lymphoblastoid cells (Raji).
- Published
- 1993
- Full Text
- View/download PDF